Can-Fite BioPharma says Eurasian Patent Office ready to grant patent for Piclidenoson

Can-Fite BioPharma announced the Eurasian Patent Office issued a notification of readiness to grant a patent covering the use of its drug candidate Piclidenoson for treating diseases associated with OCRL deficiency, such as Lowe syndrome and Dent disease 2. The company is developing Piclidenoson for Lowe syndrome with Fondazione Telethon, including an ongoing open-label Phase 2 trial.

Detected & updated continuously · Source: Nebula